1. Data on file. NewLink Genetics. 2. NewLink Genetics. NewLink Genetics completes patient enrollment in phase 3 algenpantucel-L (IMPRESS) Clinical Study. Press release. September 17, 2013. 3. National Institutes of Health. Immunotherapy study for surgically resected pancreatic cancer. http://clinicaltrials.gov/ct2/show/NCT01072981?term=newlink&rank=10. Accessed September 3, 2013.
4. National Institutes of Health. Immunotherapy study in borderline resectable or locally advanced unresectable pancreatic cancer. http://clinicaltrials.gov/ct2/show/record/NCT01836432?term=newlink&rank=5. Accessed September 3, 2013. 5. National Institutes of Health. Immunotherapy study in progressive or relapsed non-small–cell lung cancer. http://clinicaltrials.gov/ct2/show/NCT01774578?term=newlink&rank=8. Accessed September 3, 2013. 6. National Institutes of Health. A phase II study of an anti-tumor immunotherapy regimen comprised of pegylated interferon-alpha 2b and hyperacute melanoma vaccine for subjects with advanced melanoma. http://clinicaltrials.gov/ct2/show/NCT00746746?term=hyperacute+melanoma&rank=1. Accessed September 3, 2013. 7. National Institutes of Health. Vaccine treatment for hormone refractory prostate cancer. http://clinicaltrials.gov/ct2/show/NCT00105053?term=hyperacute+prostate&rank=1. Accessed September 3, 2013. 8. Mandell RB, Flick R, Staplin WR, et al. The αGal HyperAcute (®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade. Zoonoses Public Health. 2009;56(6-7):391-406. 9. Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets. 2005;9(4):831-849. 10. Jia L, Schweikart K, Tomaszewski J, et al. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol. 2008;46(1):203-211.
11. National Institutes of Health. Study of chemotherapy in combination with IDO inhibitor in metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT01792050?term=newlink&rank=6. Accessed September 3, 2013. 12. National Institutes of Health. Phase II study of sipuleucel-t and indoximod for patients with refractory metastatic prostate cancer. http://clinicaltrials.gov/ct2/show/NCT01560923?term=indoximod&rank=2. Accessed September 3, 2013.